Evidence map›Paper›PMID 42876984›Full record

ReviewVeterinary medicine international2026

Dosage of Pimobendan in Domestic Cats.

Edinete Lúcio Pereira, Luana Thamilis Alves Bezerra, Thiago Da Silva Brandão, Rosangela Maria Nunes Da Silva, Almir Pereira De Souza

Abstract readReview
In one paragraph

Review in Veterinary medicine international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Edinete Lúcio PereiraGraduate Program in Animal Science and Health, Federal University of Campina Grande (UFCG), Av. Universitária S/n-Santa Cecília, Patos 58.708-110, Paraiba, Brazil, ufcg.edu.br.ORCID https://orcid.org/0000-0003-2160-1617
Luana Thamilis Alves BezerraGraduate Program in Animal Science and Health, Federal University of Campina Grande (UFCG), Av. Universitária S/n-Santa Cecília, Patos 58.708-110, Paraiba, Brazil, ufcg.edu.br.ORCID https://orcid.org/0009-0005-3088-8279
Thiago Da Silva BrandãoGraduate Program in Animal Science and Health, Federal University of Campina Grande (UFCG), Av. Universitária S/n-Santa Cecília, Patos 58.708-110, Paraiba, Brazil, ufcg.edu.br.ORCID https://orcid.org/0000-0002-7186-8726
Rosangela Maria Nunes Da SilvaAcademic Unit of Veterinary Medicine, UFCG, Av. Universitária S/n-Santa Cecília, Patos 58.708-110, Paraiba, Brazil, ufcg.edu.br.ORCID https://orcid.org/0000-0003-3187-861X
Almir Pereira De SouzaAcademic Unit of Veterinary Medicine, UFCG, Av. Universitária S/n-Santa Cecília, Patos 58.708-110, Paraiba, Brazil, ufcg.edu.br.ORCID https://orcid.org/0000-0002-8587-5724

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Available evidence suggests that pimobendan may provide clinical benefits in the treatment of heart diseases in cats. However, its dosage is based on studies conducted in dogs, raising concerns due to differences in plasma concentrations between species. Review Question: What is the dosage of pimobendan used in domestic cats, either healthy or with heart disease? Methods: Searches in the PubMed, Web of Science, Scopus, and ScienceDirect databases were conducted between October and November 2024, a period corresponding to the execution of the search strategy. Full-text articles were included without restrictions regarding language, country, or year of publication, while gray literature was excluded. Results: Out of 371 articles screened, 15 were excluded due to duplication or lack of relevance, resulting in 10 studies being included in the final review. Pimobendan dosages ranged from 0.125 mg/kg to 0.5 mg/kg, with oral administration being predominant, typically every 12 h. Some studies used single doses to evaluate the drug's pharmacodynamics. Beneficial effects observed included improved cardiac output, enhanced left ventricular function, and reduced risk of thrombi. Common adverse effects were anorexia, vomiting, lethargy, hypotension, and arrhythmias, particularly tachycardia (4/10). The studies showed some risk of bias, such as lack of detailed information on sex, weight, and adverse effects in cats, heterogeneity in study populations, variability in pimobendan doses, and insufficient control of cardiac disease conditions. Conclusion and Clinical Relevance: Pimobendan was well tolerated in cats, with only isolated and no clinically relevant adverse effects reported, at doses ranging from 0.24 to 0.5 mg/kg or 1.25 mg/cat, with oral administration every 12 h being the recommended regimen.

Indexed as

cardiopathicdosagefelineshealthyinodilator

Identifiers

PMID42876984
PMCPMC13662733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.